IDEXX Laboratories Inc.

527.25-1.21-0.23%Vol 74.51K1Y Perf 102.77%
Apr 16th, 2021 10:41 DELAYED
BID526.35 ASK527.65
Open532.43 Previous Close528.46
Pre-Market- After-Market-
 - -%  - -
Target Price
581.25 
Analyst Rating
Strong Buy 1.50
Potential %
10.29 
Finscreener Ranking
★★★     51.35
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     45.15
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     69.62
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap45.15B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
85.28 
Earnings Date
4th May 2021

Today's Price Range

526.00532.43

52W Range

256.42573.99

5 Year PE Ratio Range

31.00103.20

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
5.09%
1 Month
4.25%
3 Months
7.97%
6 Months
24.71%
1 Year
102.77%
3 Years
170.15%
5 Years
562.81%
10 Years
1 228.79%

TickerPriceChg.Chg.%
IDXX527.25-1.2100-0.23
AAPL134.28-0.2200-0.16
GOOG2 292.64-4.0200-0.18
MSFT259.500.00000.00
XOM56.84-0.1400-0.25
WFC43.331.09002.58
JNJ160.830.44000.27
FB305.71-2.1100-0.69
GE13.48-0.0700-0.52
JPM153.991.82001.20
Financial StrengthValueIndustryS&P 500US Markets
1.30
1.80
0.60
1.59
21.00
Leverage Ratio 4.80
ProfitabilityValueIndustryS&P 500US Markets
58.00
25.70
29.20
20.90
22.77
RevenueValueIndustryS&P 500US Markets
2.08B
24.29
9.69
10.66
Earnings HistoryEstimateReportedSurprise %
Q04 20201.432.0140.56
Q03 20201.421.6919.01
Q02 20201.201.7243.33
Q01 20201.231.294.88
Q04 20190.911.0414.29
Q03 20191.131.249.73
Q02 20191.371.434.38
Q01 20191.041.1712.50
Earnings Per EndEstimateRevision %Trend
3/2021 QR1.728.86Positive
6/2021 QR2.022.02Positive
12/2021 FY7.559.26Positive
12/2022 FY8.744.42Positive
Next Report Date4th May 2021
Estimated EPS Next Report1.72
Estimates Count5
EPS Growth Next 5 Years %15.80
Volume Overview
Volume74.51K
Shares Outstanding85.63M
Trades Count2.00K
Dollar Volume251.54M
Avg. Volume459.23K
Avg. Weekly Volume316.67K
Avg. Monthly Volume426.40K
Avg. Quarterly Volume466.64K

IDEXX Laboratories Inc. (NASDAQ: IDXX) stock closed at 528.46 per share at the end of the most recent trading day (a 2.78% change compared to the prior day closing price) with a volume of 438.73K shares and market capitalization of 45.15B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 9300 people. IDEXX Laboratories Inc. CEO is Jonathan J. Mazelsky.

The one-year performance of IDEXX Laboratories Inc. stock is 102.77%, while year-to-date (YTD) performance is 5.72%. IDXX stock has a five-year performance of 562.81%. Its 52-week range is between 256.42 and 573.99, which gives IDXX stock a 52-week price range ratio of 85.28%

IDEXX Laboratories Inc. currently has a PE ratio of 74.50, a price-to-book (PB) ratio of 67.69, a price-to-sale (PS) ratio of 20.85, a price to cashflow ratio of 66.90, a PEG ratio of 2.32, a ROA of 27.12%, a ROC of 39.71% and a ROE of 140.98%. The company’s profit margin is 22.77%, its EBITDA margin is 29.20%, and its revenue ttm is $2.08 Billion , which makes it $24.29 revenue per share.

Of the last four earnings reports from IDEXX Laboratories Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.72 for the next earnings report. IDEXX Laboratories Inc.’s next earnings report date is 04th May 2021.

The consensus rating of Wall Street analysts for IDEXX Laboratories Inc. is Strong Buy (1.5), with a target price of $581.25, which is +10.29% compared to the current price. The earnings rating for IDEXX Laboratories Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

IDEXX Laboratories Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

IDEXX Laboratories Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.40, ATR14 : 20.16, CCI20 : 202.24, Chaikin Money Flow : 0.22, MACD : 0.69, Money Flow Index : 87.46, ROC : 10.28, RSI : 53.59, STOCH (14,3) : 97.22, STOCH RSI : 1.00, UO : 68.12, Williams %R : -2.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of IDEXX Laboratories Inc. in the last 12-months were: Brian P. Mckeon (Option Excercise at a value of $7 876 851), Brian P. Mckeon (Sold 131 247 shares of value $54 270 553 ), Bruce L. Claflin (Option Excercise at a value of $1 476 124), Bruce L. Claflin (Sold 20 811 shares of value $9 111 786 ), Daniel M. Junius (Option Excercise at a value of $1 144 071), Daniel M. Junius (Sold 1 342 shares of value $1 505 469 ), Giovani Twigge (Option Excercise at a value of $4 796 935), Giovani Twigge (Sold 65 026 shares of value $25 823 011 ), James F. Polewaczyk (Option Excercise at a value of $1 312 407), James F. Polewaczyk (Sold 16 264 shares of value $4 860 515 ), Jonathan J. Mazelsky (Option Excercise at a value of $1 599 925), Jonathan J. Mazelsky (Sold 18 774 shares of value $9 750 203 ), Jonathan W. Ayers (Option Excercise at a value of $12 396 427), Jonathan W. Ayers (Sold 539 846 shares of value $180 172 097 ), Kathy V. Turner (Option Excercise at a value of $0), Kathy V. Turner (Sold 2 690 shares of value $809 690 ), M. Anne Szostak (Option Excercise at a value of $1 875 772), M. Anne Szostak (Sold 27 320 shares of value $10 555 655 ), Michael J. Lane (Option Excercise at a value of $202 184), Michael J. Lane (Sold 2 154 shares of value $1 040 920 ), Nimrata Hunt (Option Excercise at a value of $130 629), Nimrata Hunt (Sold 4 874 shares of value $2 034 169 ), Rebecca M. Henderson (Option Excercise at a value of $2 712 073), Rebecca M. Henderson (Sold 35 740 shares of value $11 816 682 ), Sharon E. Underberg (Option Excercise at a value of $199 904), Sophie V. Vandebroek (Option Excercise at a value of $488 213), Sophie V. Vandebroek (Sold 3 046 shares of value $1 639 357 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
4 (80.00 %)
4 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (25.00 %)
1 (20.00 %)
1 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.40
Strong Buy
1.40

IDEXX Laboratories Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

CEO: Jonathan J. Mazelsky

Telephone: +1 207 556-0300

Address: One IDEXX Drive, Westbrook 04092, ME, US

Number of employees: 9 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

59%41%

Bearish Bullish

61%39%

News

Stocktwits